STOCK TITAN

ING Groep N.V. (ING) 424B Filings

ING NYSE

Here are the 424B prospectus supplements from ING Groep N.V. (ING) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 424B covers the supplement that carries the terms of a priced offering, so if you follow ING and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ING filings page.

Rhea-AI Summary

ING Groep N.V. is offering $1,500,000,000 aggregate principal amount of 4.803% Callable Fixed-to-Floating Rate Senior Notes due 2032 and $1,500,000,000 aggregate principal amount of 5.420% Callable Fixed-to-Floating Rate Senior Notes due 2037.

The notes bear fixed interest until their call dates (March 23, 2031 and March 23, 2036) and convert to quarterly SOFR-based floating rates thereafter (plus 1.260% for 2032 notes and 1.610% for 2037 notes, subject to a 0.00% minimum). The issue date is March 23, 2026, and proceeds, net of underwriting fees and expenses, are estimated at $2,991,326,778 for general corporate purposes.

Rhea-AI Summary

ING Groep N.V. is offering callable senior notes in three series due in 2032 and 2037, including fixed-to-floating and floating-rate tranches, to be issued under its Senior Debt Securities Indenture.

The notes will be unsecured, rank pari passu with other senior unsecured obligations, bear fixed interest through specified call dates and then reset to a floating rate tied to the SOFR Index Average plus a spread (subject to a 0.00% minimum rate). The prospectus supplement permits substitution or variation of terms following certain Tax Events or Loss Absorption Disqualification Events and acknowledges that the notes are subject to Dutch bail-in powers. The Issuer intends to apply to list the notes on the NYSE under symbols ING32A, ING37 and ING32B. Interest and redemption mechanics, SOFR discontinuation fallbacks, and limited holder remedies are described in the supplement.